Stock Events

Calliditas Therapeutics AB 

$39.07
18
+$0.07+0.18% Thursday 19:59

Statistics

Day High
39.35
Day Low
39.01
52W High
41.9
52W Low
15.25
Volume
12,391
Avg. Volume
20,330
Mkt Cap
1.16B
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

23MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-0.92
-0.52
-0.13
0.27
Expected EPS
-0.14
Actual EPS
-0.88

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CALT. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Analyst Ratings

39.25$Average Price Target
The highest estimate is $40.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

About

Health Technology
Pharmaceuticals: Major
Manufacturing
Pharmaceutical Preparation Manufacturing
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.
Show more...
CEO
Renee J. Aguiar-Lucander
Employees
219
Country
US
ISIN
US13124Q1067
WKN
000A2P57K

Listings